FDA approved zenocutuzumab-zbco for post-systemic-therapy, NRG1 fusion–positive unresectable/metastatic cholangiocarcinoma, addressing an ultra-rare molecular ...

Veppanu represents a scientific milestone as the first-ever proteolysis-targeting chimera (PROTAC) to receive FDA approval.

Patient recounts IL‑2 therapy chills, rigors, ICU seizure scare, and recovery—what treatment feels like and why monitoring ...

Indications span MF and PV in adults, plus acute/chronic GVHD in patients ≥12 years, positioning XR as a once-daily ...

Inside TIL therapy: daily hospital routines, caregiver support, chemo and infusion steps, and what recovery questions patients ask most. Interleukin-2 (IL-2) is often the most challenging part of ...

Motherhood is framed as lifelong emotional tethering, with caregiving intensified when a child is seriously ill and requiring sustained physical, emotional, and spiritual labor. A four-year caregiving ...

A mother reflects on the "tethered heart" of caregiving, sharing her journey through her son’s rare cancer and offering solidarity to all mothers.

Molecular/genomic profiling is expanding precision selection of systemic therapy and may enable immunotherapy-driven organ ...

SEER 1975–2023 analysis demonstrated a long-term mortality inflection from rising rates to sustained declines, with the ...

The result of this multidisciplinary synergy is a clear path forward. According to Kasper, the patient leaves the visit with ...

Fast Track status aims to accelerate development of an autologous dendritic cell immunotherapy for advanced cutaneous melanoma with limited durable benefit from current standards in many patients.

Dr. Samyukta Mullangi shares how AI can help patients understand oncology visits, ask better questions, and feel more engaged in their care.